Key result
ACEI/ARB use linked to ~83% lower in-hospital mortality in acute decompensated heart failure.
Why the study?
Acutely decompensated heart failure is a common cause of hospitalization and mortality worldwide, but its epidemiology and prognostic factors required exploration in Cameroonian patients.
Does ACEIs/ARBs use reduce in-hospital mortality in patients with acutely decompensated systolic heart failure in Cameroon?
Cohort (n=142)
No
Does ACEIs/ARBs use reduce in-hospital mortality in patients with acutely decompensated systolic heart failure in Cameroon?
Odds Ratio: 0.17 (95% CI 0.02–0.81)
p-value: p=0.006
This study highlights the high burden and 20.4% in-hospital mortality of acutely decompensated heart failure in Cameroon, and underscores the protective association of guideline-directed medical therapy like ACEIs/ARBs.
ACEI/ARB use was associated with lower in-hospital mortality in this Cameroonian cohort; observational data leave open causal benefit pending randomized confirmation.
No takes yet. Share an insight, caveat, or question.
Lemogoum et al. (2020) conducted a cohort in Acutely decompensated heart failure with reduced ejection fraction (n=142). ACEIs/ARBs use vs. No ACEIs/ARBs use was evaluated on In-hospital mortality (OR 0.17, 95% CI 0.02-0.81, p=0.006). In Cameroonian patients hospitalized for acutely decompensated heart failure, use of ACEIs/ARBs was associated with significantly reduced in-hospital mortality (OR 0.17).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: